MacroGenics Files 8-K Report
Ticker: MGNX · Form: 8-K · Filed: 2024-04-03T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: MGNX
TL;DR
MGNX filed an 8-K, check for financial updates and other events.
AI Summary
On April 3, 2024, MacroGenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that MacroGenics, Inc. has made a regulatory disclosure, which could contain important updates for investors regarding financial statements or other material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report, and the provided excerpt does not contain information that inherently increases risk.
Key Players & Entities
- MACROGENICS, INC. (company) — Registrant
- Nasdaq (company) — Stock Exchange
FAQ
What specific "Other Events" are reported in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported.
Are there any new financial statements or exhibits attached to this 8-K filing?
The filing indicates that "Financial Statements and Exhibits" are part of the report, but the excerpt does not provide their content.
What is the trading symbol for MacroGenics, Inc. on the Nasdaq?
The trading symbol for MacroGenics, Inc. on the Nasdaq Global Select Market is MGNX.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 3, 2024.
What is the principal executive office address for MacroGenics, Inc.?
The principal executive offices of MacroGenics, Inc. are located at 9704 Medical Center Drive, Rockville, Maryland 20850.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-04-03 17:24:34
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share MGNX Nasdaq Global Select Mar
Filing Documents
- mgnx-20240403.htm (8-K) — 29KB
- exhibit991tamarack.htm (EX-99.1) — 26KB
- macrogenics20logo_jpgormat.jpg (GRAPHIC) — 136KB
- 0001125345-24-000065.txt ( ) — 369KB
- mgnx-20240403.xsd (EX-101.SCH) — 2KB
- mgnx-20240403_lab.xml (EX-101.LAB) — 21KB
- mgnx-20240403_pre.xml (EX-101.PRE) — 12KB
- mgnx-20240403_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 3, 2024, MacroGenics, Inc. issued a press release entitled "MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures." A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release dated April 3 , 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 3, 2024 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel